Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin

Gazzerro, Patrizia; Malfitano, Anna Maria; Proto, Maria; Pisanti, Simona; Caruso, Maria Gabriella; Notarnicola, Maria; Messa, Caterina; Laezza, Chiara; Misso, Gabriella; Caraglia, Michele; Bifulco, Maurizio

doi:10.3892/or_00000619

Cited by 16 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colorectal Cancer It despite being easily treated by resection is highly heterogeneous and therefore at risk for drug resistance because of frequent epigenetic changes [158,159]. Clinical data regarding treatment of this disease with cannabinoids also remain minimal; however, a significant association between increases in CB1 receptor expression in colorectal cancer samples, cancer stage, and prognosis has been observed [160][161][162]. Interestingly, cannabinoids may act synergistically, in a cannabinoid receptor-independent manner, with chemotherapeutics, such as 5-fluorouracil, in eliciting their antiproliferative action on colorectal cancers [163].…”

Section: Gliomas and Glioblastomasmentioning

confidence: 99%

Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals

2022

View full text Add to dashboard Cite

Background: There is a growing interest in the use of cannabis (and its extracts), as well as CBD oil (hemp extracts containing cannabidiol), for therapeutic purposes. While there is reason to believe that cannabinoids may be efficacious for a number of different diseases and syndromes, there exist limited objective data supporting the use of crude materials (CBD oil, cannabis extracts, and/or cannabis itself). Summary: In the present review, we examined data for pure cannabinoid compounds (dronabinol, nabilone, and CBD), as well as partially purified medicinal cannabis extracts (nabiximols), to provide guidance on the potential therapeutic uses of high-THC cannabis and CBD oil. In general, data support a role for cannabis/cannabinoids in pain, seizure disorders, appetite stimulation, muscle spasticity, and treatment of nausea/vomiting. Given the biological activities of the cannabinoids, there may be utility in treatment of central nervous system disorders (such as neurodegenerative diseases, PTSD, and addiction) or for the treatment of cancer. However, those data are much less compelling. Key Message: On balance, there are reasons to support the potential use of medical cannabis and cannabis extract (Δ9-THC-dominant or CBD-dominant), but much more careful research is required.

show abstract

Section: Gliomas and Glioblastomasmentioning

confidence: 99%

Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals

2022

View full text Add to dashboard Cite

show abstract

“…For many years, both CBD and SR have been investigated for their antitumor potential. The increasing and constant attention on their potential comes from their pleiotropic effects in cancer and related mechanisms, ascribable to cannabinoid receptor (CBR)-dependent or -independent actions [11][12][13][14][15].…”

Section: Discussionmentioning

confidence: 99%

“…Both SR and CBD were found to be able to inhibit tumor cell proliferation with several mechanisms [11][12][13][14]. In this work, we focused our attention on the ability of SR and CBD to control the tumor microenvironment dynamic in breast cancer cells.…”

Section: Sr and Cbd Control Transcriptional Activation Of Tumor-relat...mentioning

confidence: 99%

“…A growing amount of evidence reports the involvement of the endocannabinoid system in cancer modulation, affecting proliferation, migration, invasion, and metastases [11][12][13][14][15]. Furthermore, modulation of the endocannabinoid system has been reported to interfere with components of the TME, although its role in tumor-stroma interactions is unclear [16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rimonabant and Cannabidiol Rewrite the Interactions between Breast Cancer Cells and Tumor Microenvironment

Proto,

Fiore,

Bifulco

et al. 2023

IJMS

View full text Add to dashboard Cite

The spread of breast cancer to distant sites is the major cause of death in breast cancer patients. Increasing evidence supports the role of the tumor microenvironment (TME) in breast cancers, and its pathologic assessment has become a diagnostic and therapeutic tool. In the TME, a bidirectional interplay between tumor and stromal cells occurs, both at the primary and metastatic site. Hundreds of molecules, including cytokines, chemokines, and growth factors, contribute to this fine interaction to promote tumor spreading. Here, we investigated the effects of Rimonabant and Cannabidiol, known for their antitumor activity, on reprogramming the breast TME. Both compounds directly affect the activity of several pathways involved in breast cancer progression. To mimic tumor–stroma interactions during breast-to-lung metastasis, we investigated the effect of the compounds on growth factor secretion from metastatic breast cancer cells and normal and activated lung fibroblasts. In this setting, we demonstrated the anti-metastatic potential of the two compounds, and the membrane array analyses highlighted their ability to alter the release of factors involved in the autocrine and paracrine regulation of tumor proliferation, angiogenesis, and immune reprogramming. The results enforce the antitumor potential of Rimonabant and Cannabidiol, providing a novel potential tool for breast cancer TME management.

show abstract

Cannabinoids in the landscape of cancer

Mangal

Erridge

Habib

et al. 2021

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Introduction Cannabinoids are a group of terpenophenolic compounds derived from the Cannabis sativa L. plant. There is a growing body of evidence from cell culture and animal studies in support of cannabinoids possessing anticancer properties. Method A database search of peer reviewed articles published in English as full texts between January 1970 and April 2021 in Google Scholar, MEDLINE, PubMed and Web of Science was undertaken. References of relevant literature were searched to identify additional studies to construct a narrative literature review of oncological effects of cannabinoids in pre-clinical and clinical studies in various cancer types. Results Phyto-, endogenous and synthetic cannabinoids demonstrated antitumour effects both in vitro and in vivo. However, these effects are dependent on cancer type, the concentration and preparation of the cannabinoid and the abundance of receptor targets. The mechanism of action of synthetic cannabinoids, (−)-trans-Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) has mainly been described via the traditional cannabinoid receptors; CB1 and CB2, but reports have also indicated evidence of activity through GPR55, TRPM8 and other ion channels including TRPA1, TRPV1 and TRPV2. Conclusion Cannabinoids have shown to be efficacious both as a single agent and in combination with antineoplastic drugs. These effects have occurred through various receptors and ligands and modulation of signalling pathways involved in hallmarks of cancer pathology. There is a need for further studies to characterise its mode of action at the molecular level and to delineate efficacious dosage and route of administration in addition to synergistic regimes.

show abstract

Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin

Cited by 16 publications

References 23 publications

Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals

Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals

Rimonabant and Cannabidiol Rewrite the Interactions between Breast Cancer Cells and Tumor Microenvironment

Cannabinoids in the landscape of cancer

Contact Info

Product

Resources

About